BRAF<sup>V600E</sup>‐PROTAC versus inhibitors in melanoma cells: Deep transcriptomic characterization
PROTAC-targeting BRAF<sup>V600E</sup> demonstrates enhanced MAPK suppression, reduced early resistance and distinct transcriptional effects compared to traditional inhibitors. It represents a promising strategy for overcoming resistance in melanoma treatment.
Authors
- Solomon Alhassan
- Youssef Errami (ORCID: https://orcid.org/0000-0002-0432-4331)
- Zakaria Y. Abd Elmageed (ORCID: https://orcid.org/0000-0003-4031-0348)
- Mourad Zerfaoui (ORCID: https://orcid.org/0000-0002-8511-8934)
- Emad Kandil (ORCID: https://orcid.org/0000-0001-5895-4403)
- Guangdi Wang (ORCID: https://orcid.org/0000-0002-3999-8213)
- Joe Abi‐Rached (ORCID: https://orcid.org/0000-0003-3227-6143)
Institutions
- Tulane University (US)
- Emory University (US)
- Xavier University of Louisiana (US)
- Moffitt Cancer Center (US)
- Edward Via College of Osteopathic Medicine (US)
Publication Details
- Journal
- Clinical and Translational Medicine
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1002/ctm2.70251
- Citations
- 5
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 4.03
Funders
- National Institutes of Health